This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Nov;51(17):2578-9.

doi: 10.1016/j.ejca.2015.10.001.

Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role

Tim Eisen¹

Affiliations

PMID: 26613659
DOI: 10.1016/j.ejca.2015.10.001

Comment

Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role

Tim Eisen. Eur J Cancer. 2015 Nov.

. 2015 Nov;51(17):2578-9.

doi: 10.1016/j.ejca.2015.10.001.

Author

Tim Eisen¹

Affiliation

¹ University of Cambridge, Biomedical Research Campus, Cambridge, UK; AstraZeneca, Cambridge, UK. Electronic address: tgqe2@medschl.cam.ac.uk.

PMID: 26613659
DOI: 10.1016/j.ejca.2015.10.001

No abstract available

PubMed Disclaimer

Comment on

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B, Choueiri TK. Albiges L, et al. Eur J Cancer. 2015 Nov;51(17):2580-6. doi: 10.1016/j.ejca.2015.08.017. Epub 2015 Sep 4. Eur J Cancer. 2015. PMID: 26346135

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information